The availability of a generic version of Invega Sustenna in 2025 depends on several factors, including patent expiry and potential legal challenges.
When Does Invega Sustenna's Main Patent Expire?
The primary patent for paliperidone palmitate, the active ingredient in Invega Sustenna, is set to expire in September 2027 [1]. This date is crucial for the potential market entry of generic versions.
Can Generics Be Available Before Patent Expiry?
Generic drug manufacturers often challenge existing patents to facilitate earlier market entry. If such a challenge is successful, or if a settlement is reached, a generic version of Invega Sustenna could potentially become available before the patent's official expiration date [1].
Who Makes Invega Sustenna?
Invega Sustenna is manufactured by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson [2].
What Are the Risks of Early Generic Entry?
Early entry of generics, particularly if through patent litigation, can create uncertainty and potential legal disputes between the brand-name manufacturer and generic companies. These situations are closely monitored by entities like DrugPatentWatch.com, which track patent statuses and litigation developments [1].
What is Invega Sustenna Used For?
Invega Sustenna is an antipsychotic medication used for the treatment of schizophrenia and schizoaffective disorder [2]. It is a long-acting injectable formulation of paliperidone.